MilliporeSigma, the US life science business of Merck KGaA, has agreed to acquire Mirus Bio, a Madison, Wisconsin-based life-sciences company, for $600 million.  

Mirus Bio, part of Gamma Biosciences, a life-sciences tools platform created by the investment firm, KKR, specializes in the development and commercialization of transfection reagents, such as TransIT-VirusGEN. Transfection reagents play a role in the production of viral vector-based gene therapies. 

This deal is anticipated to close in the third quarter of 2024 and is subject to regulatory clearance and other customary closing conditions. 

Source: MilliporeSigma